Featured Publications
Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans
Ranganathan M, De Aquino JP, Cortes-Briones JA, Radhakrishnan R, Pittman B, Bhakta S, D’Souza D. Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans. Psychopharmacology 2019, 236: 3209-3219. PMID: 31187152, DOI: 10.1007/s00213-019-05273-5.Peer-Reviewed Original ResearchConceptsCOMT rs4680 polymorphismMemory deficitsCOMT genotypeVal/Val individualsRs4680 polymorphismSubjective effectsTest dayCatechol-O-methyl transferase (COMT) enzymePsychotomimetic effectsCognitive effectsCognitive dataCannabinoid-dopamine interactionsAcute responseHuman brainIntravenous THCPlacebo-controlled studyRole of dopaminergicCatechol-O-methyl transferaseDopaminergic signalingAcute pharmacological inhibitionDeficitsCannabinoid effectsDopaminergic toneHealthy subjectsDrug development effortsFeasibility and effects of galantamine on cognition in humans with cannabis use disorder
Sugarman DE, De Aquino JP, Poling J, Sofuoglu M. Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacology Biochemistry And Behavior 2019, 181: 86-92. PMID: 31082417, PMCID: PMC6545124, DOI: 10.1016/j.pbb.2019.05.004.Peer-Reviewed Original ResearchConceptsCannabis use disorderEffects of galantamineMeasures of attentionSelf-report measuresAdministration of galantamineOutpatient treatment periodPlacebo-controlled trialParallel-group trialTime pointsAcute cannabis intoxicationSignificant adverse effectsLong-term useSignificant main effectResponse inhibitionCognitive effectsCognitive performanceCognitive outcomesBaseline variablesCognitive AssessmentCognitive deficitsCannabis withdrawalTreatment periodProcognitive effectsGalantamine administrationBaseline sessions
2022
Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans
De Aquino JP, DeVito EE, Xie C, Meyerovich J, Parida S, Gueorguieva R, Sofuoglu M. Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. Psychopharmacology 2022, 239: 2809-2818. PMID: 35554617, DOI: 10.1007/s00213-022-06162-0.Peer-Reviewed Original ResearchImpact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science
De Aquino JP, MacLean RR, Gueorguieva R, DeVito EE, Eid T, Sofuoglu M. Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology 2022, 27: e13161. PMID: 35229960, PMCID: PMC8903077, DOI: 10.1111/adb.13161.Peer-Reviewed Original ResearchConceptsAbuse potentialPositive subjective drug effectsSubjective drug effectsHuman laboratory studiesPositive subjective effectsAttention functionSmoking urgesOvernight abstinencePotential therapeutic effectsEffects of nicotineHeart rate increaseDelivery rateDependent smokersExperimental sessionsSubjective effectsNicotine dependenceIntravenous nicotineBlood pressureSaline infusionAcute effectsTherapeutic effectHeart rateDrug effectsAcute responseCrossover design
2020
Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study
De Aquino JP, Sofuoglu M, Stefanovics EA, Rosenheck RA. Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study. The American Journal Of Drug And Alcohol Abuse 2020, 46: 812-822. PMID: 33035104, DOI: 10.1080/00952990.2020.1818248.Peer-Reviewed Original ResearchConceptsNon-medical opioid usePosttraumatic stress disorderOpioid useNon-medical opioidsPTSD symptomsCannabis useStress disorderSubstance useBaseline cannabis useImpact of cannabisSevere PTSD symptomsIntensive PTSD treatmentMore PTSD symptomsPTSD treatmentU.S. veteransSymptomsVA studyCannabisVeteransOpioidsSubstitution agentsBaselineDaysDisordersTreatment
2019
Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only
De Aquino JP, Sofuoglu M, Stefanovics E, Rosenheck R. Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only. The American Journal Of Drug And Alcohol Abuse 2019, 45: 527-537. PMID: 31112429, DOI: 10.1080/00952990.2019.1607363.Peer-Reviewed Original ResearchConceptsDrug use disordersOpioid use disorderUse disordersOpioid prescriptionsCo-occurring opioid use disordersNational Veterans Health Administration dataVeterans Health Administration dataCo-occurring opioidEmergency department visitsHealth Administration dataInpatient psychiatric admissionCannabis use disorderOpioid prescribingClinical characteristicsED visitsDepartment visitsInpatient admissionsPsychiatric admissionsFiscal year 2012Lower riskPatientsBivariate analysisAdministration dataDisordersHigher likelihoodEffects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis
Gupta S, De Aquino JP, D’Souza D, Ranganathan M. Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis. Psychopharmacology 2019, 236: 2635-2640. PMID: 30919005, PMCID: PMC6697616, DOI: 10.1007/s00213-019-05235-x.Peer-Reviewed Original ResearchConceptsDissociative Symptoms ScalePANSS positive scalePsychotomimetic effectsHuman laboratory studiesRole of dopaminePsychosis-like effectsHaloperidol conditionNegative Syndrome ScalePANSS positive scoreDopaminergic antagonismPositive scalePlacebo conditionResponder analysisSyndrome ScaleSymptom ScaleDouble-blind studyEffects of haloperidolDopaminergic signalingOral haloperidolIndividualsOnly respondersPositive scoreIntravenous administrationHealthy individualsHaloperidol